Prelude Capital Management, LLC Akero Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 16,300 shares of AKRO stock, worth $521,762. This represents 0.03% of its overall portfolio holdings.
Number of Shares
16,300
Previous 16,300
-0.0%
Holding current value
$521,762
Previous $467,000
-0.0%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$253 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$227 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$189 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$179 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$168 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.49B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...